2024
Rapid Remission of Plaque Psoriasis With Bimekizumab Treatment.
Abdin R, Gharib R, Bunick C, Issa N. Rapid Remission of Plaque Psoriasis With Bimekizumab Treatment. Journal Of Drugs In Dermatology 2024, 23: 694-696. PMID: 39093648, DOI: 10.36849/jdd.8381.Peer-Reviewed Original ResearchConceptsPlaque psoriasisIL-17AIL-17FAnti-IL-17 biologicsSafety of bimekizumabPathogenesis of psoriasisMonoclonal immunoglobulin G1Psoriasis patientsBimekizumabTreatment optionsClinical trialsPsoriasisMedical literatureClearance timeImmunoglobulin G1Rapidity of responseTreatmentPatientsEfficacyClearancePlaqueBrodalumabCytokinesPathogenesisReceptorsScientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease
Armillei M, Lomakin I, Del Rosso J, Grada A, Bunick C. Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease. Antibiotics 2024, 13: 270. PMID: 38534705, PMCID: PMC10967556, DOI: 10.3390/antibiotics13030270.Peer-Reviewed Original ResearchSoft tissue infectionsTetracycline class antibioticsTreatment of dermatological diseasesMechanism of protein synthesis inhibitionClindamycin useStaphylococcal infectionsTissue infectionsClinical presentationAnti-inflammatory propertiesHidradenitis suppurativaEffective antibioticsTreatment optionsClindamycinClinical evidenceAcne vulgarisClinical basisProtein synthesis inhibitionDermatological indicationsAmeliorate inflammationAntibiotic resistanceDermatology practiceBacterial ribosomeDermatological diseasesClass antibioticsLesion formation
2023
Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis
Murrell D, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Bunick C. Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis. Clinical And Experimental Dermatology 2023, 48: 623-630. PMID: 36794376, DOI: 10.1093/ced/llad033.Peer-Reviewed Original ResearchConceptsAdverse eventsVehicle groupControl studyGlobal assessmentInvestigator's Global AssessmentMost adverse eventsApplication site reactionsTopical treatment optionsProportion of participantsIGA scoreCutaneous manifestationsMean agePhase IIbTreatment optionsCongenital ichthyosisSubtypesAutosomal recessive lamellar ichthyosisOintment formulationLamellar ichthyosisRecessive ichthyosisIchthyosisScoresBaselineGreater proportionParticipants
2022
Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management
Daniele S, Kim S, Grada A, Moore A, Suozzi K, Bunick C. Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management. American Journal Of Clinical Dermatology 2022, 24: 199-223. PMID: 36539678, DOI: 10.1007/s40257-022-00746-4.Peer-Reviewed Original ResearchConceptsTruncal acne vulgarisAcne vulgarisTruncal acneHalf of patientsFacial acne vulgarisSignificant psychosocial burdenAvailable treatment optionsCommon skin disorderTreatment guidelinesPsychosocial burdenTreatment optionsTruncal involvementPatient managementFacial lesionsClinical problemSkin disordersUpper armCosmetic approachSebaceous glandsCurrent MedicalSkin areasPatientsAcneFocused reviewFurther investigation
2020
Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy.
Eldirany SA, Ho M, Bunick CG. Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy. The Yale Journal Of Biology And Medicine 2020, 93: 19-27. PMID: 32226331, PMCID: PMC7087057.Peer-Reviewed Original ResearchConceptsBiologic therapyTumor necrosis factor alphaFirst-line treatmentTreatment of psoriasisNecrosis factor alphaClinical responseInterleukin-17Interleukin-23Line treatmentPrescribing practicesPsoriasis therapyInflammatory disordersTreatment optionsTherapeutic decisionsClinical dataFactor alphaPatient safetyTherapySignificant differencesBiologic medicinesDrugsEpitope locationMolecular differencesTreatmentMedications